2.61
+0.15(+6.10%)
Currency In USD
| Previous Close | 2.46 |
| Open | 2.45 |
| Day High | 2.62 |
| Day Low | 2.38 |
| 52-Week High | 6.52 |
| 52-Week Low | 1.09 |
| Volume | 1.59M |
| Average Volume | 2.05M |
| Market Cap | 185.73M |
| PE | -1.64 |
| EPS | -1.59 |
| Moving Average 50 Days | 2.54 |
| Moving Average 200 Days | 2.21 |
| Change | 0.15 |
If you invested $1000 in C4 Therapeutics, Inc. (CCCC) since IPO date, it would be worth $102.39 as of November 01, 2025 at a share price of $2.61. Whereas If you bought $1000 worth of C4 Therapeutics, Inc. (CCCC) shares 3 years ago, it would be worth $254.88 as of November 01, 2025 at a share price of $2.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
GlobeNewswire Inc.
Oct 16, 2025 11:08 AM GMT
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab Potential to Earn up
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
GlobeNewswire Inc.
Oct 01, 2025 11:00 AM GMT
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clini
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
GlobeNewswire Inc.
Sep 20, 2025 3:00 PM GMT
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population Respons